Literature DB >> 16540230

Selection of RNA aptamers against recombinant transforming growth factor-beta type III receptor displayed on cell surface.

Shoji P Ohuchi1, Takashi Ohtsu, Yoshikazu Nakamura.   

Abstract

In most cases, anti-protein aptamers are selected by systematic evolution of ligands by exponential enrichment (SELEX) using purified recombinant protein targets. Cell surface proteins, however, are not easy targets for SELEX due to the difficulties associated with their purification. Here, we developed a novel SELEX procedure (referred to as TECS-SELEX) in which cell-surface displayed recombinant protein is directly used as the selection target. Using this method, we isolated RNA aptamers against transforming growth factor-beta type III receptor expressed on Chinese hamster ovary (CHO) cells. One of the RNA aptamers has a dissociation constant in the 1 nM range and competed with transforming growth factor-beta to bind to the cell surface receptor in vitro.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16540230     DOI: 10.1016/j.biochi.2006.02.004

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  47 in total

1.  In vitro selection of a peptide antagonist of growth hormone secretagogue receptor using cDNA display.

Authors:  Shingo Ueno; Sayaka Yoshida; Anupom Mondal; Kazuya Nishina; Makoto Koyama; Ichiro Sakata; Kenju Miura; Yujiro Hayashi; Naoto Nemoto; Koichi Nishigaki; Takafumi Sakai
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-20       Impact factor: 11.205

Review 2.  Recent advances in understanding oligonucleotide aptamers and their applications as therapeutic agents.

Authors:  Khaled S Allemailem; Ahmad Almatroudi; Mohammed A Alsahli; Ghaiyda Talal Basfar; Faris Alrumaihi; Arshad Husain Rahmani; Amjad Ali Khan
Journal:  3 Biotech       Date:  2020-11-24       Impact factor: 2.406

3.  Crystallization and preliminary X-ray diffraction studies of an RNA aptamer in complex with the human IgG Fc fragment.

Authors:  Shigeru Sugiyama; Yusuke Nomura; Taiichi Sakamoto; Tomoya Kitatani; Asako Kobayashi; Shin Miyakawa; Yoshinori Takahashi; Hiroaki Adachi; Kazufumi Takano; Satoshi Murakami; Tsuyoshi Inoue; Yusuke Mori; Yoshikazu Nakamura; Hiroyoshi Matsumura
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2008-09-30

4.  DNA aptamers that target human glioblastoma multiforme cells overexpressing epidermal growth factor receptor variant III in vitro.

Authors:  Yan Tan; Yu-sheng Shi; Xi-dong Wu; Hui-yu Liang; Yu-bo Gao; Shu-ji Li; Xing-mei Zhang; Fang Wang; Tian-ming Gao
Journal:  Acta Pharmacol Sin       Date:  2013-12       Impact factor: 6.150

5.  Structural and molecular basis for hyperspecificity of RNA aptamer to human immunoglobulin G.

Authors:  Shin Miyakawa; Yusuke Nomura; Taiichi Sakamoto; Yoshiki Yamaguchi; Koichi Kato; Satoko Yamazaki; Yoshikazu Nakamura
Journal:  RNA       Date:  2008-04-25       Impact factor: 4.942

Review 6.  Aptamers in immunotherapy.

Authors:  Claudia M Dollins; Smita Nair; Bruce A Sullenger
Journal:  Hum Gene Ther       Date:  2008-05       Impact factor: 5.695

7.  RNA aptamers and their therapeutic and diagnostic applications.

Authors:  Katherine Germer; Marissa Leonard; Xiaoting Zhang
Journal:  Int J Biochem Mol Biol       Date:  2013-03-31

Review 8.  Trends in the Design and Development of Specific Aptamers Against Peptides and Proteins.

Authors:  Maryam Tabarzad; Marzieh Jafari
Journal:  Protein J       Date:  2016-04       Impact factor: 2.371

9.  Labelling of live cells using fluorescent aptamers: binding reversal with DNA nucleases.

Authors:  Hideyuki Terazono; Yu Anzai; Mikhail Soloviev; Kenji Yasuda
Journal:  J Nanobiotechnology       Date:  2010-04-13       Impact factor: 10.435

10.  Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics.

Authors:  John S Vorhies; John J Nemunaitis
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.